Therapy Area
Allergy & Immunology
Cardiology
Dermatology
Diabetes
Flagship Journal
Gastroenterology
General Healthcare
Hematology
Hepatology
Innovations
Interventional Cardiology
Microbiology & Infectious Diseases
Nephrology
Neurology
Oncology
Radiology
Reproductive Health
Respiratory
Rheumatology
Urology
Podcasts
Journals
Webinars
Congress Hub
Toolkit
Paediatric Growth Calculator
DVT Risk Calculator
Due Date Calculator
Mean Arterial Pressure (MAP) Calculator
Collaborate
About
EQOH
Careers
Contact Us
Media Pack
Editorial Enquiries
Contributors & Authors
Submit a Paper
Media Partners
Pharma Partners
EMJ Interactive
EMJ GOLD
CME
search
Join
FREE
This site is intended for healthcare professionals
You must accept all conditions before being able to view the post
Continue
EUR
USA
EUR
USA
Therapy Area
Allergy & Immunology
Cardiology
Dermatology
Diabetes
Flagship Journal
Gastroenterology
General Healthcare
Hematology
Hepatology
Innovations
Interventional Cardiology
Microbiology & Infectious Diseases
Nephrology
Neurology
Oncology
Radiology
Reproductive Health
Respiratory
Rheumatology
Urology
Podcasts
Journals
Webinars
Congress Hub
Toolkit
Paediatric Growth Calculator
DVT Risk Calculator
Due Date Calculator
Mean Arterial Pressure (MAP) Calculator
Collaborate
About
EQOH
Careers
Contact Us
Media Pack
Editorial Enquiries
Contributors & Authors
Submit a Paper
Media Partners
Pharma Partners
EMJ Interactive
EMJ GOLD
CME
Join
FREE
Filter Content:
Allergy & Immunology
Cardiology
Dermatology
Diabetes
Flagship Journal
Gastroenterology
General Healthcare
Hematology
Hepatology
Innovations
Interventional Cardiology
Microbiology & Infectious Diseases
Nephrology
Neurology
Oncology
Radiology
Reproductive Health
Respiratory
Rheumatology
Urology
Abstracts
Urology
2
Mins
27 Apr 2026
Factors Associated with Inferior Outcomes in Patients with Advanced Urothelial Carcinoma
Enfortumab vedotin plus pembrolizumab (EV+P) is the preferred first-line (1L) regimen for patients with advanced urothelial carcinoma…
Urology
1
Mins
27 Apr 2026
Results of 20 Years of Follow-Up from ERSPC Rotterdam
Data from a 15-year follow-up of the ProtecT trial, which randomised men to radical prostatectomy (RP), radiotherapy (RT), or active…
Urology
2
Mins
27 Apr 2026
Ultrasound Navigation in Robot-Assisted Percutaneous Access
Percutaneous access is essential in procedures such as percutaneous nephrolithotomy, biopsy, and ablation, requiring precise…
Urology
1
Mins
27 Apr 2026
Novel Paediatric Low-Dose CT Protocol for Urolithiasis Assessment
Ultrasonography is the recommended first-line investigation for the diagnosis of paediatric urolithiasis.1 Despite higher sensitivity and…
Urology
1
Mins
27 Apr 2026
Comparing Automated and Semi-Automated Methods for Measuring Kidney Stone Volumes
With recent emphasis placed on using stone volumes in surgical outcomes research,1-6 there is a need to assess the accuracy and…
Urology
1
Mins
27 Apr 2026
9-Valent HPV Vaccine and Genital Wart Recurrence
Human papillomavirus (HPV) is the most common sexually transmitted infection worldwide,1 with most sexually active individuals acquiring…
Radiology
1
Mins
17 Apr 2026
AI or Radiologist Interpretation for Prostate Cancer Diagnosis
Following the PRECISION trial, prostate multiparametric MRI has been adopted as the first-line investigation for suspected prostate cancer…
Radiology
1
Mins
17 Apr 2026
Focal Cortical Dysplasia Type IIb: Correlation of Histological Data with Typical MRI Patterns
Resistant epilepsies account for approximately 30% of all forms of epilepsy, particularly in patients with focal…
Loading posts...
« Previous
1
2
3
4
5
…
130
Next »
We’ve noticed you’re accessing
from
North/South America.
View
View